To further clarify whether inhibition of ITGB5 and activation of TIMP1 and TMEM176B affect tumor cell migration, we also used dCas9-KRAB-mediated CRISPRi technology to knock down ITGB5 expression, and used dCas9-VPR-mediated CRISPRa technology to induce TIMP1 and TMEM176B activation. The gene discussed is ITGB5; the disease is neoplasm.